Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growth. The Danish pharma ...

In its fourth-quarter results statement, Novo Nordisk said that it had started to increase the supply of starting doses for Wegovy in the US since the start of the year thanks to those investments ...

For the first time since May, Novo Nordisk is gradually increasing the supply of its highly sought-after weight loss drug ...

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been ... the companies’ manufacturing endeavors, ZS’ supply chain and manufacturing practice lead, Anshul Agarwal ...

Novo Nordisk underperformed as its blockbuster weight loss drug, Wegovy, faced supply constraints that restricted its starting dose figures. In contrast, Eli Lilly’s key competing product ...